Syndax price target raised to $34 from $31 at JPMorgan

JPMorgan analyst Anupam Rama raised the firm’s price target on Syndax to $34 from $31 and keeps an Overweight rating on the shares. The analyst says top-line pivotal data for monotherapy revumenib from the AUGMENT-101 cohort in mutations in nucleophosmin cute myeloid leukemia patients is on track for Q4. The firm continues to view revumenib as having first- and best-in-class potential in the menin inhibitor space, particularly in the monotherapy acute leukemia setting. It believes this remains a key underappreciated near-term value driver for the shares.